Grants

The Department of Thoracic Surgery is supported in its intensive research activities by various national and international foundations and institutions with financial donations (grants).  The following employees received for their projects a grant and are mentioned by name in the Annual Report.

Here you can find the archive of all Annual Reports of the Division of Surgical Research (University and University Hospital Zurich) as of 2002.

2016

Thoracic Surgery Grants 2016

​Source

​Project title

​Project management

2015

Thoracic Surgery Grants 2015

Source​

​Project title

​Project management

Swiss National Science Foundation

​From asbestos-exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment

​E. Felley-Bosco

​Baumgarten Stiftung

Preclinical Malignant Pleural Mesothelioma models to accelerate clinical research on targeted therapy

​E. Felley-Bosco

Walter Bruckerhoff Stiftung

​Targeting epigenetic deregulation

​E. Felley-Bosco

Polianthes Foundation

​Overcoming development of resistance and progression to mesenchymal phenotype in mesothelioma

​E. Felley-Bosco

Polianthes Foundation

​Comprehensive investigation of predictive biomarkers for chemotherapy response and novel drug targets in patients with MPM by next generation sequencing

I. Schmitt-Opitz

Krebsforschung Schweiz

​Mesoscape 001-pS6: Construction of a multi-institutional European tissue bank

​I. Schmitt-Opitz

Swiss National Science Foundation

​Magnetic resonance imaging for the detection of chronic lung allograft rejection in mouse lung transplantation

W. Jungraithmayr (Co-Applicant)
Applicant: PD Dr. A. Boss

​Swiss National Science Foundation, Förderungsprofessuren

Malignant Pleural Mesothelioma - an integral approach for better outcome

​I. Schmitt-Opitz

Forschungskredit der Universität Zürich

​Attenuation of acute lung allograft rejection by CD26 inhibition – a preclinical model

​W. Jungraithmayr

​Stiftung für wissenschaftliche Forschung, Zürich

​Lung tumor growth reduction by CD26 inhibition

​W. Jungraithmayr

​Assistenz-Professur an der UZH

​Lungentransplantation

​W. Jungraithmayr

Förderungsprogramm "Filling the Gap", FTG-1617-02

Attenuation of acute lung allograft rejection by CD26 inhibition – a preclinical model

​W. Jungraithmayr

​Hermann Klaus-Stiftung

​Primary lung tumor growth inhibition by CD26

​W. Jungraithmayr

Innovationspool

Assessment and reconditioning of donor lungs with ex vivo lung perfusion system

I. Inci

​Lungenliga Zürich

​Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia

​I. Inci

Hermann-Klaus Stiftung​

​Ex vivo reconditioning of donor lungs with Trimetazidine after prolonged cold ischemia

​I. Inci

​Hermann-Klaus Stiftung​

​Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia

I. Inci​

Hartmann-Müller Stiftung, Zürich​

​The role of cytokine filtration during ex vivo lung perfusion

​I. Inci

Lunge Zürich

​​MicroRNAs as prognostic and predictive tumor markers assisting the selection of patients with Malignant Pleural Mesothelioma for multimoda-lity treat-ment

​​I. Schmitt-Opitz, M. Kirschner

​Dr. Arnold U. u. Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung

(Krebsstiftung)

In vivo study of the efficacy of a dual phosphatidylinositol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma​

​W. Weder, I. Schmitt-Opitz

​Krebsliga Zürich

​Prognostic Marker for Malignant Pleural Mesothelioma

I. Schmitt-Opitz

BECON AG Foundation 

​Prognostische Marker für das Maligne Pleuramesotheliom

​I. Schmitt-Opitz

Vontobel Stiftung

​MikroRNAs als prognostische und prädikative Tumormarker für die multimodale Behand-lung des malignen Pleura-mesothelioms

​I. Schmitt-Opitz, M. Kirschner

​Stiftung für angewandte Krebsforschung

​Activity based protein profiling in human lung cancer biopsies

​W. Weder, S. Hillinger, S. Arni

Novartis Pharma AG Basel


 

​Identification and validation of drug targets and biomarkers for COPD/emphysema and other end-stage lung disease

​W. Weder, S. Hillinger

EMDO-Stiftung, Switzerland

Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation

​W. Jungraithmayr

​Universität Zürich, Projektförderung (Abt.I-III)

​Suppression of lung tumor growth by CD26/DPP4-inhibition

W. Jungraithmayr​

​Kurt und Senta Herrmann-Stiftung, Liechtenstein, Vaduz

​Blockade of CD26/DPP4-costimulation to improve lung transplant

survival

​W. Jungraithmayr

Helene Bieber-Fonds

The CD26-costimlatory pathway is critical for Th17-mediated lung transplant improvement

​ W. Jungraithmayr

2014

Thoracic Surgery Grants 2014

​Source

​Project title

Project manager

​Matching Fund UZH 2012
​Preclinical investigation of the role of hedgehog signaling on mesothelioma recurrence
​I.Schmitt-Opitz
​Matching Fund UZH 2011
​Prognostic Marker for Malignant Pleural Mesothelioma
​I.Schmitt-Opitz
​Cancer League Zurich
​Prognostic Marker for Malignant Pleural Mesothelioma
​I.Schmitt-Opitz
​BECON AG Foundation
​Prognostic Marker for Malignant Pleural Mesothelioma
​I.Schmitt-Opitz
​Vontobel Stiftung
​Micro-RNAs as Prognostic and Predicative Tumor Markers for the Multimodal Treatment of Malignant Mesothelioma
​I.Schmitt-Opitz
​Krebsliga Zürich
​Activity based protein profiling in human lung cancer biopsies
​W.Weder,S.Hillinger, S.Arni
​Novartis Pharma AG, Basel
Identification and validation of drug targets and biomarkers for COPD/emphysema and other end-stage lung disease​
​W.Weder, S.Hillinger
​Matching Fund UZH 2012
​Improvement of ischemia-reperfusion injury in murine lung transplants by regenerative stern cells via inhibition of CD26/DPPIV
​W.Jungraithmayr
​EMDO Foundation 2013, Zurich
​Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation
​W.Jungraithmayr
​University Zurich, Project Funding (Dept. I-III)
​​Suppression of lung tumor growth by CD26/DPP4-Inhibition
​W.Jungraithmayr
​Hermann-Klaus Foundation, Zurich
​Ex vivo reconditioning of donor lungs with Trimetazidine after prolonged cold ischemia
​I.Inci

​Hartmann-Müller Foundation, Zurich

​Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia
​I.Inci

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2013

Thoracic Surgery Grants 2013

Source​Project title

​Project manager

Swiss National Science Foundation
Immunotherapy for lung cancer
S. Hillinger
Swiss National Science Foundation
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic injury in a mouse
W. Jungraithmayr
Swiss National Science Foundation
Micro computer tomography for in vivo imaging
W. Jungraithmayr
(Co-Applicant)
Applicant: PD Dr. A. Boss
Hartmann-Müller Foundation, Zurich - 2012
Improvement of ischemia-reperfusion injury in muring lung transplants by stem cells via inhibition of DPP4 (Act No.: 1591)
W. Jungraithmayr
Lung League Zurich
Reconditioning of lung transplants damaged by gastric acid
non-heartbeating donor
I. Inci
​Innovation pool
​Assessment and recondi-tioning of donor lungs with ex vivo lung perfusion system
​I.Inci
​Lung League Zurich
​Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia
​I.Inci
​Swiss National Science Foundation
​In-Vivo Bioreactor for the reepithelialization of tissue engineered trachea
W.Weder​
Dr. Arnold U. a. Susanne Huggenberger-Bischoff Foundation for Cancer Research
(Cancer Research)
In vivo study of the efficacy of a dual phosphatidylino-sitol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma
W. Weder, I. Schmitt-Opitz
​BECON AG Foundation
​Prognostic Marker for the Malignant Pleuramesothelioma
​W. Weder, I. Schmitt-Opitz
Matching Fund UZH 2011
Malignant Pleural Mesothelioma - an integral approach for better outcome
I. Schmitt-Opitz
Matching Fund UZH 2012
Preclinical investigation of the role of hedgehog signaling on
mesothelioma recurrence
I. Schmitt-Opitz
Matching Fund UZH 2011
Prognostic Marker for Malig-nant Pleural Mesothelioma
I. Schmitt-Opitz
Cancer League Zurich
Prognostic Marker for Malig-nant Pleural Mesothelioma
I. Schmitt-Opitz
​Swiss National Science Foundation
Professorships
​Malignant Pleural Mesothelioma - an integral approach for better outcome
​I. Schmitt-Opitz
Cancer League Zurich
Activity based protein profiling in human lung cancer biopsies
W. Weder, S. Hillinger,
S. Arni
Novartis Pharma AG Basel
Identification and validation of drug targets and biomarkers for COPD/ emphysema and other end-stage lung disease
W. Weder, S. Hillinger
Matching Fund UZH 2012
Improvement of ischemia-reperfusion injury in murine lung transplants by regenerative stem cells via inhibition of CD26/DPPIV
W. Jungraithmayr
Matching Fund UZH 2011
Tolerance induction via NK cell mediated elimination of donor antigen presenting cells in mouse lung transplants
W. Jungraithmayr
EMDO Foundation 2013, Zurich, Switzerland
Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation
W. Jungraithmayr
2012

Thoracic Surgery Grants 2012

Source

Project title

Project manager

Hartmann-Müller Foundation, Zurich - 2012
Improvement of ischemia-reperfusion injury in muring lungtransplants by stem cells via inhibition of DPP4 (Ges-nr: 1591)
W. Jungraithmayr
Swiss National Science Foundation
Professorships
Malignant Pleural Mesothelioma - an integral approach for
better outcome
I. Schmitt-Opitz
Swiss National Science Foundation
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic
injury in a mouse
W. Jungraithmayr
Swiss National Science Foundation
Immune targeted therapy for lung cancer
S. Hillinger
Swiss National Science Foundation
In-Vivo Bioreactor for the reepithelialization of tissue engineered
trachea
W. Weder
Swiss National Science Foundation
Micro computer tomography for in vivo imaging
W. Jungraithmayr (Co-
Applicant) Applicant: PD
Dr. A. Boss
Swiss National Science Foundation
Magnetic resonance imaging for the detection of chronic lung allograft rejection in mouse lung transplantation
W. Jungraithmayr (Co-
Applicant) Applicant: PD
Dr. A. Boss
Lung League Zurich
Reconditioning of lung transplants damaged by gastric acid
non-heartbeating donor
I. Inci
Dr. Arnold U. a. Susanne Huggenberger-Bischoff Foundation for Cancer Research
(Cancer Research) Co-applicant
In vivo study of the efficacy of a dual phosphatidy-linositol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma
W. Weder, I. Schmitt-
Opitz
2011

Thoracic Surgery Grants 2011

Source

Project title

Project manager

Swiss National Science Foundation
Immune targeted therapy for lung cancer
S. Hillinger
Swiss National Science Foundation
NF In-Vivo Bioreactor for the reepithelialization of tissue engineered trachea
W.Weder
Swiss National Science Foundation
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic injury in a mouse lung transplantation model
W. Jungraithmayr
Swiss National Science Foundation
Funded professorship Isabelle Schmitt-Opitz
I. Schmitt-Opitz
Covidien Inc
Covidien LUN-06-002
W. Weder
Cancer League Zurich
Adjuvant intrapleural rinsing solution after pleuropneumonectomy after malignant pleuramesothelioma
I. Schmitt-Opitz
F. Hoffmann-La Roche Ltd., Berne
ETOP Lungscape Database collaboration between ETOP and Chinese
investigators
W. Weder
Lung League
Lung League Ex vivo evaluation and resuscitation of human donor lungs rejected for transplantation
W. Weder
ETOP European Thoracic Oncology Platform
ETOP Lungscape
W. Weder
Cancer League Zurich
Activity based protein profiling in human lung cancer biopsies
W. Weder
2010

Thoracic Surgery Grants 2010

Source

​Project title

​Project manager

Swiss National Science Foundation
Immune targeted therapy for lung cancer
S. Hillinger
Swiss National Science Foundation
Trachea reconstruction using novel tissue
engineered constructs
W. Weder
Swiss National Science Foundation
The role of CD26/DPP IV and SDF-1 in pulmonary
ischemic injury in a mouse lung transplantation model
W. Jungraithmayr
Cancer League Zurich
Prognostic markers for malignant pleural mesothelioma
I. Schmitt-Opitz
Cancer League Zurich
Establishment of an integrated tumor tissue platform
and its application for comprehensive analyses of
molecular parameters in lung tumors
W. Weder
Cancer League Zurich
Adjuvant intrapleural rinsing solution after pleuropneumonectomy after malignant pleuramesothelioma
I. Schmitt-Opitz

Fellowship European Society of Medical Oncology
Intrapleural therapy after surgery for malignant pleural
mesothelioma
I. Schmitt-Opitz
Lung League
Attenuation of ischemia-reperfusion injury by N-Acetylcysteine
after lung transplantation
I.Inci
Lung League
Reconditioning of category 3 non-heart beating donor
lungs insulted to gastric aspiration: Utilization of ex vivo
lung perfusion system
I.Inci
Dr. Arnold U. a. Susanne Huggenberger-Bischoff Foundation for Cancer Research
"Activity based protein profiling in human lung cancer biopsies
S. Arni
Cancer League Zurich
Preclinical pharmacocinetic study for evaluation oif intrapleural
treatment with Cisplatin-fibrin after pneumonectomy for malig-
nant pleural mesothelioma
I. Schmitt-Opitz
Becon AG
Prognostic Marker for the Malignant Pleuramesothelioma
Tabstitel

Inhaltstitel

Inhalt

AkkordeonTitel

Inhaltstitel

Inhalt

AkkordeonTitel

Inhaltstitel

Inhalt

AkkordeonTitel

Inhaltstitel

Inhalt

AkkordeonTitel

Inhaltstitel

Inhalt